<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: <z:chebi fb="3" ids="3638">Chloroquine</z:chebi>, an anti-malarial <z:chebi fb="0" ids="17362">quinoline</z:chebi>, is structurally similar to <z:chebi fb="0" ids="28593">quinidine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Both drugs have been shown to block ion channels </plain></SENT>
<SENT sid="2" pm="."><plain>We tested the hypothesis that <z:chebi fb="3" ids="3638">chloroquine</z:chebi>'s mode of interaction with the vestibule of the cytoplasmic domain of the inward rectifier <z:chebi fb="120" ids="26216">potassium</z:chebi> channel Kir2.1 makes it a more effective I(K1) blocker and anti-fibrillatory agent than <z:chebi fb="0" ids="28593">quinidine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: We used comparative molecular modelling and ligand docking of the three-dimensional structures of <z:chebi fb="0" ids="28593">quinidine</z:chebi> and <z:chebi fb="3" ids="3638">chloroquine</z:chebi> in the intracellular domain of Kir2.1 </plain></SENT>
<SENT sid="4" pm="."><plain>Simulations predicted that <z:chebi fb="3" ids="3638">chloroquine</z:chebi> effectively blocks <z:chebi fb="120" ids="26216">potassium</z:chebi> flow by binding at the centre of the ion permeation vestibule of Kir2.1 </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, <z:chebi fb="0" ids="28593">quinidine</z:chebi> binds the vestibular side, only partially blocking ion movement </plain></SENT>
<SENT sid="6" pm="."><plain>We tested the modelling predictions in Kir2.1-expressing human embryonic kidney (HEK)-293 cells </plain></SENT>
<SENT sid="7" pm="."><plain>The half-maximal inhibitory concentration for <z:chebi fb="3" ids="3638">chloroquine</z:chebi> block of I(K1) was 1.2 µM, while that of <z:chebi fb="0" ids="28593">quinidine</z:chebi> was 57 µM </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, we used optical mapping of Langendorff-perfused mouse hearts with cardiac-specific Kir2.1 up-regulation to compare the anti-fibrillatory effects of the drugs </plain></SENT>
<SENT sid="9" pm="."><plain>In five of six hearts, 10 μM <z:chebi fb="0" ids="28593">quinidine</z:chebi> slowed the frequency but did not terminate the tachyarrhythmia </plain></SENT>
<SENT sid="10" pm="."><plain>In five of five hearts, 10 μM <z:chebi fb="3" ids="3638">chloroquine</z:chebi> terminated the <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, restoring sinus rhythm </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="28593">Quinidine</z:chebi> only partially blocks I(K1) </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="3" ids="3638">Chloroquine</z:chebi> binds at the centre of the ion permeation vestibule of Kir2.1, which makes it a more effective I(K1) blocker and anti-fibrillatory agent than <z:chebi fb="0" ids="28593">quinidine</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>Integrating the structural biology of drug-ion channel interactions with cellular electrophysiology and optical mapping is an excellent approach to understand the molecular mechanisms of anti-arrhythmic drug action and for drug discovery </plain></SENT>
</text></document>